Eli Lilly's LLY.N GLP-1 drug tirzepatide yields greater weight loss on average than Novo Nordisk's NOVOb.CO semaglutide, but at a greater expense to muscles and connective tissues, according to a study published this week ahead of peer review.
Tirzepatide, sold as Zepbound and Mounjaro, and semaglutide, under the brand names Wegovy and Ozempic, have become wildly popular for weight loss and have demonstrated other health benefits, such as heart-protective properties. But there has been concern that they induce loss of muscle and other components of lean body mass along with fat.
The researchers analyzed data on roughly 1,800 patients using tirzepatide and 6,200 using semaglutide.
Read Full Article Here
